Abstract. Acromegaly is caused by excessive secretion of growth hormone (GH), and a resultant persistent elevation of insulin-like growth factor-1 (IGF-1) levels. Diabetes mellitus is accompanied in some acromegalic patients with insulin resistance. We encountered a type-2 diabetic patient who had a poorly controlled glycemic state and was diagnosed as acromegaly with normal IGF-1 levels. The patient showed definite acromegalic features. However, in the first screening test, GH levels were high and IGF-1 levels were inappropriately normal so the results were not close to the diagnosis of acromegaly. After moderate glycemic control, an oral glucose suppression test was performed, showing no suppressed GH response. TRH test revealed paradoxical increases in growth hormone levels and a brain MRI discovered a pituitary adenoma. After several-months insulin treatment, IGF-1 levels were increased to the abnormal state and GH levels were decreased without treatment for acromegaly. Here we report the rare case of acromegaly that presents inappropriately normal IGF-1 levels at the time of diagnosis in uncontrolled type 2 diabetic patient and shows increased IGF-1 levels after glycemic control with insulin therapy. When evaluating acromegaly in type 2 diabetes under poorly controlled glycemia, cautious IGF-1 analysis is needed after sufficient glycemic control.
ACROMEGALY is an uncommonly diagnosed disorder with an annual estimated incidence of 3 to 4 cases per 1 million people [1] . It is characterized by hypersecretion of growth hormone (GH). Generally, the most common cause of acromegaly is a pituitary adenoma. Diabetes mellitus develops in 25% of patients with acromegaly, and is secondary to increase in GH secretion which induces insulin resistance [2] .
Many physiologic effects of GH are mediated indirectly through IGF-1 (insulin-like growth factor-1), which is hepatic in origin [3] . Age-and gendermatched serum IGF-1 are elevated in acromegaly and an IGF-1 level provides a useful laboratory screening measure when clinical features raise the possibility of acromegaly [1] . In insulin-dependent diabetes, however, GH/IGF-1 axis could be disturbed due to decreased insulin, which is necessarily needed to produce IGF-1 in hepatocytes [4] [5] [6] . In addition, from a previous study insulin-dependent diabetic patients had elevated GH concentrations and inappropriately normal IGF-1 levels [7] . However, the IGF-1 levels related to newly diagnosed acromegaly in underlying diabetic patients was not definitely uncovered, especially type 2 diabetes.
Here we report a case of a poorly controlled type 2 diabetic patient who presented increased GH levels but inappropriately normal IGF-1 levels, confusing the diagnosis of acromegaly, and who finally showed increased IGF-1 levels after glycemic control.
Case Report
A 75-year-old man was admitted to our hospital for control and assessment of diabetes and suspicious acromegaly. The patient had suffered from diabetes for six years and had been unable to control the blood glucose level adequately for the last four months. On admission, the patient exhibited clarity of consciousness. His body temperature was 36.6°C, his pulse rate was 70/min, and he had a regular blood pressure of 110/80 mmHg. The patient was 165 cm tall, and weighed 59 kg.
The patient's thyroid gland was not palpable. Craniocervical examination revealed frontal bossing, mandibular enlargement, prognathism, large fleshy nose and coarse facial features. There was no audible systolic murmur. Neither hepatomegaly nor splenomegaly was detected. The patient also did not exhibit peripheral edema or decreased skin turgor. Neurologic tests suggested mild sensory and autonomic nerve disorders, probably due to diabetic polyneuropathy and autonomic neuropathy. His body mass index (BMI) was 22 kg/m 2 ; fasting plasma glucose concentration, 257 mg/dl; fasting plasma insulin, 3.21 nU/ml; glycosylated hemoglobin (HbA1C), 18.9% ; fasting plasma C-peptide, 0.15 ng/ml; post-prandial 2 hr plasma Cpeptide, 0.62 ng/ml. No islet cell antibody was detected.
Urinalysis revealed no ketonuria, and creatinine clearance was within the normal range. The patient's blood chemistry on admission was as follows: aspartate aminotransferase, 19 IU/L (normal range 10-40); alanine aminotransferase, 45 IU/L (5-40); total bilirubin, 0.58 g/dL (0.2-1.3); total protein, 6.1 g/dL (6.3-8. The patient took dietary advice and started to be treated with intermediate-acting insulin twice daily. Total daily dose of insulin was 50 units. The patient's diabetes was not adequately controlled during admission.
The endocrinological tests including measurements of GH and IGF-1 levels were executed to screen acromegaly (Table 1 ). Contrary to our expectation, IGF-1 and IGFBP-3 were in the normal range (212.6 ng/ml and 1583.5 ng/ml, respectively), even though the growth hormone level was extremely increased (40.10 ng/ml). Therefore, oral glucose tolerance test (OGTT) was carried out in order to confirm the diagnosis of acromegaly after two-week glycemic control with insulin (Table 2A ). The morning insulin injection was omitted and the test was commenced with the patient still fasting. The serum growth hormone levels were measured at basal and at 30-minute intervals for 2 hours after a 75 g load of oral glucose. The patient's fasting GH was found to be elevated (21.9 ng/ml) and failed to fall to normal level during the OGTT. In the subsequent TRH test 5 days after OGTT, the patient's growth hormone levels were measured at basal, 30, 60, 90 and 120 minutes after TRH administration (Table 2B) . These results demonstrated paradoxical increases in growth hormone levels after TRH stimulation. Magnetic resonance imaging (MRI) of the pituitary gland showed a microadenoma (1.0 × 0.5 cm) (Fig. 1) . Based on the above results, acro- megaly due to a pituitary adenoma was confirmed. After the patient was managed with several-months insulin treatment without any treatment for the acromegaly, HbA1C levels was 8.4%, the GH levels were decreased to 17.02 ng/ml, which was still high, and the IGF-1 levels were increased to 695.3 ng/ml and, later to 956.4 ng/ml at 4 months after insulin treatment (Table 1). The patient was recommended to undergo an operation of the pituitary microadenoma but he refused it for the fear of operation. He is being closely observed in office up to recently with moderately controlled glycemic status, showing the last IGF-1 and HbA1c levels of 8.7% and 1177.2 ng/ml, respectively.
Discussion
Acromegaly is caused by excessive secretion of growth hormone (GH), and a resultant persistent elevation of insulin-like growth factor-1 (IGF-1) levels. The delay in diagnosis may exacerbate complications due to GH hypersecretion. Thus, the timely diagnosis of acromegaly is crucial. The diagnosis of acromegaly is based on both clinical and biochemical evidence. Once acromegaly is suspected, serum IGF-1 levels should be measured because a high degree of correlation has been noted between serum IGF-1 and acromegaly-associated factors [8] . The random levels of growth hormone are usually not helpful in diagnosing acromegaly because GH is secreted in a pulsatile fashion. Acromegaly in the absence of high IGF-1 levels is extremely rare. This relationship makes IGF-1 an ideal screening test [1] .
However, some disorders including malnutrition, malabsorption, anorexia nervosa, liver cirrhosis, renal failure and type 1 diabetes mellitus, shows discrepancies between GH and IGF-1 [9] . In type 1 diabetics with poorly controlled glycemia, circulating GH is increased but plasma IGF-1 level is low because of insulin deficiency [4, 7] . As a sufficient amount of insulin is needed in order to induce expression of GH receptors on hepatocytes, an insulin deficiency in portal vein might cause a decrease in the number of GH receptors, reflected by GH binding protein (GHBP) [10] [11] [12] [13] . As a consequence, elevated GH levels to overcome the decreased number of GH receptors induce hepatic GH resistance and decrease hepatic generation of IGF-1.
Such low IGF-1 levels were not observed in one reported case in a poorly controlled type 1 patient with acromegaly by Herlihy and Perros, which was maybe due to early insulin therapy, decreasing hepatic GH resistance [14] . High levels of GH, however, were detected during OGTT, indicating GH resistance. It has not been known with certainty whether this 'acquired/ functional GH insensitivity' also has an influence on type 2 diabetic patients with acromegaly. Many studies have shown that diabetes was accompanied by a decrease in IGF-1 levels, but others have shown different results, in which IGF-1 levels showed no change, or were increased [7] . The reason for these various results might be due to an age-related variation in IGF-1 levels [7] . After adjusting this variation the study showed that diabetic patients had significantly lower IGF-1 levels than normal subjects. IGF-1 levels were, on the average, 40-50% lower in diabetic patients than in the normal subjects after correction for age, a decrease equal to that which occurs after fasting for 3 days [15] . The degree of diabetic control had been focused on in several studies. Amiel et al. found significantly higher IGF-1 levels in patients receiving chronic subcutaneous insulin infusion than in those receiving conventional therapy, indicating sufficient insulin therapy guarantees IGF-1 production [16] . However, this study was based on only type 1 diabetic patients aged 13-22 yr.
It seems to be possible that the same situation applies to our type 2 diabetic patients, who had a deranged metabolic state at admission and hardly enough pancreatic β-cell capacity to secrete insulin to reverse this state. His extremely high HbA1c and glucose levels with insulin deficiency accompanied much higher GH and lower IGF-1 levels than expected in acromegalic patient, as mentioned above as 'hepatic GH resistance', of which the main cause was considered to be extreme insulin deficiency. Though the patient showed unequivocal acromegalic appearance and increased GH levels, a random IGF-1 level as a screening tool was normal and did not help our patient to be diagnosed as acromegaly. In poorly controlled type 2 diabetic patients, random IGF-1 levels as a screening tool for the diagnosis of acromegaly needs so much caution because IGF-1 levels were under-estimated as seen in our case and therefore, even though random IGF-1 levels was normal, confirmative tests (including OGTT) should be performed to diagnose acromegaly after sufficient glycemic control in type 2 diabetic patients. Even after a well-controlled glycemic status in type 2 diabetes, IGF-1 check-up is also important, because it reflects real IGF-1 levels.
In conclusion this paper reports an uncontrolled type 2 diabetic patient who had definite acromegalic features but showed inappropriately normal IGF-1, confusing the diagnosis of acromegaly.
